D
David Kardatzke
Researcher at Genentech
Publications - 16
Citations - 4608
David Kardatzke is an academic researcher from Genentech. The author has contributed to research in topics: Pirfenidone & Idiopathic pulmonary fibrosis. The author has an hindex of 8, co-authored 14 publications receiving 3913 citations.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
TL;DR: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W. Noble,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Marilyn K. Glassberg,David Kardatzke,Talmadge E. King,Lisa Lancaster,Steven A. Sahn,Javier Szwarcberg,Dominique Valeyre,Roland M. du Bois +11 more
TL;DR: In this article, the CAPACITY program was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
Steven D. Nathan,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Ian Glaspole,Marilyn K. Glassberg,David Kardatzke,Monica Daigl,Klaus Uwe Kirchgaessler,Lisa Lancaster,David J. Lederer,Carlos Alberto de Castro Pereira,Jeffrey J. Swigris,Dominique Valeyre,Paul W. Noble +14 more
TL;DR: Several analytic approaches demonstrated that pirfenidone therapy is associated with a reduction in the relative risk of mortality compared with placebo over 120 weeks.
Pirfenidone in patients with idiopathic pulmonary fi brosis (CAPACITY): two randomised trials
King,Paul W. Noble,C Albera,Williamson Z. Bradford,Costabel U,Marilyn K. Glassberg,David Kardatzke,T. E. King,Lisa Lancaster,Javier Szwarcberg,Dominique Valeyre +10 more
TL;DR: The CAPACITY programme was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival
David S. Alberts,Christian Marth,Ronald D. Alvarez,Gary A. Johnson,Mariusz Bidziński,David Kardatzke,Williamson Z. Bradford,Jeff Loutit,David H. Kirn,Mary C Clouser,Maurie Markman +10 more
TL;DR: Treatment with IFN-gamma 1b in combination with carboplatin/paclitaxel does not have a role in the first-line treatment of advanced ovarian cancer.